DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Søren Holm - 1 Duncan Minty - 1 Kengo Sakurada - 1 you've - 1 Colm Holmes - 1 — - 1 Holmes - 1 Inga Beale - 1
Top related locs:
London State Copenhagen Denmark Australia United States
Top related orgs:
Consumers - 1 Caliber - 1 Insurance - 1 Sompo Holdings - 1 Aviva - 1 Allianz Holdings — - 1 of Actuaries - 1 State Farm - 1

Search resuls for: "International Congress"


2 mentions found


☆ Insurance companies have discovered devious new ways to rip you off
  + stars: | 2023-10-23 | by ( Jathan Sadowski | ) www.businessinsider.com   time to read: +16 min
Unfortunately, as premiums for everything from home insurance to car insurance skyrocket, more of us are being forced to dwell on the opaque and convoluted insurance industry. AdvertisementAdvertisementTo determine that magic price tag, insurance companies drill down into the nitty-gritty details of your life. I'll go even further: To boost their own profits, insurance companies are becoming increasingly antisocial and antagonistic. To boost their own profits, insurance companies are becoming increasingly anti-social and antagonistic. The stuff of insurance is far too important to be left to the insurance industry.
Persons: Søren Holm, Duncan Minty, Kengo Sakurada, you've, Colm Holmes, —, Holmes, Inga Beale, Beale, ProPublica, Cigna Organizations: Consumers, Caliber, Insurance, Sompo Holdings, Aviva, Allianz Holdings —, of Actuaries, State Farm, Farm, New York Times, of Information Technology, Monash University Locations: London, State
☆ Bayer says Parkinson's stem cell therapy improves symptoms in initial trial
  + stars: | 2023-08-28 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
FRANKFURT, Aug 28 (Reuters) - Bayer (BAYGn.DE) said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson’s disease symptoms in an early 12-patient trial. The German drugmaker announced the trial had succeeded in a brief summary in June, saying it was a first for a stem-cell Parkinson's therapy, but held back details for a medical conference. The five participants on a lower dose experienced 0.72 hours longer per day with well-controlled symptoms on average and the time of worsening symptoms was 0.75 hours shorter per day for them. For BlueRock's experimental therapy, the researchers took human pluripotent embryonic stem cells and transformed them into dopamine-producing nerve cells. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.
Persons: BlueRock, Christian Rommel, Bayer's, Britain's, Ludwig Burger, Susan Fenton Organizations: FRANKFURT, Bayer, U.S, drugmaker, International Congress, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, Thomson Locations: Copenhagen, Denmark, Australia, United States
0 next >>
Total: 2